Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. scores highest on Nitro (65) and lowest on Price (6). Its PosiPenta is 40.95 out of 100, around the middle of similar companies.
On the Penta Grid this week, Alaunos Therapeutics, Inc. is Grid #505 of 837 in the Healthcare sector in United States, and Grid #2,793 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Alaunos Therapeutics, Inc. | 40.95 | 6 | 50 | 65 | 52 | 32 |
| NeuroOne Medical Technologies Corporation | 37.95 | 26 | 58 | 11 | 41 | 53 |
| Tempest Therapeutics, Inc. | 18.60 | 0 | 42 | 5 | 9 | 37 |
| Theriva Biologics, Inc. | 45.24 | 89 | 43 | 28 | 33 | 32 |
| Bullfrog AI Holdings, Inc. | 40.93 | 35 | 63 | 28 | 48 | 32 |
| MetaVia Inc. | 33.07 | 37 | 19 | 16 | 42 | 51 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.49 |
| P/B ratio | 11.81 |
EEarnings
| Trailing EPS | ₹-166.70 |
| Forward EPS | ₹-56.83 |
NNitro
| Price | 249.10 |
| 52-week high | 426.22 |
| 52-week low | 68.19 |
| Fall from 52-week high | 41.6% |
TTorque
| Return on equity (ROE) | -185.95% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | -0.87 |
| Market cap | ₹72 Cr |
| Insider holding | 13.21% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Alaunos Therapeutics, Inc.'s PosiPenta score?
Alaunos Therapeutics, Inc.'s PosiPenta is 40.95 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Alaunos Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Alaunos Therapeutics, Inc. is Grid #505 of 837 in the Healthcare sector in United States, and Grid #2,793 of 4,000 in United States.
Which PosiPenta pillar is strongest for Alaunos Therapeutics, Inc.?
Nitro (momentum), with a score of 65 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Alaunos Therapeutics, Inc.?
Price (valuation), with a score of 6 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.